Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Kinetic analysis of PI3K reactions with fluorescent PIP2 derivatives.

Huang W, Jiang D, Wang X, Wang K, Sims CE, Allbritton NL, Zhang Q.

Anal Bioanal Chem. 2011 Oct;401(6):1881-8. doi: 10.1007/s00216-011-5257-z. Epub 2011 Jul 26.

2.

Fluorescent phosphatidylinositol 4,5-bisphosphate derivatives with modified 6-hydroxy group as novel substrates for phospholipase C.

Wang X, Barrett M, Sondek J, Harden TK, Zhang Q.

Biochemistry. 2012 Jul 3;51(26):5300-6. Epub 2012 Jun 22.

3.

New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway.

Nehmé R, Nehmé H, Saurat T, de-Tauzia ML, Buron F, Lafite P, Verrelle P, Chautard E, Morin P, Routier S, Bénédetti H.

Anal Bioanal Chem. 2014 Jun;406(15):3743-54. doi: 10.1007/s00216-014-7790-z. Epub 2014 May 11.

PMID:
24817345
4.

PI3K: a potential therapeutic target for cancer.

Chen Y, Wang BC, Xiao Y.

J Cell Physiol. 2012 Jul;227(7):2818-21. doi: 10.1002/jcp.23038. Review.

PMID:
21938729
5.

Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.

Xie X, Tang B, Zhou J, Gao Q, Zhang P.

Oncol Rep. 2013 Aug;30(2):773-82. doi: 10.3892/or.2013.2520. Epub 2013 Jun 5.

PMID:
23743572
6.

A fluorogenic, small molecule reporter for mammalian phospholipase C isozymes.

Huang W, Hicks SN, Sondek J, Zhang Q.

ACS Chem Biol. 2011 Mar 18;6(3):223-8. doi: 10.1021/cb100308n. Epub 2011 Jan 10.

7.

New phosphatidylinositol 3-kinase inhibitors for cancer.

Bowles DW, Jimeno A.

Expert Opin Investig Drugs. 2011 Apr;20(4):507-18. doi: 10.1517/13543784.2011.562192. Review.

PMID:
21395485
8.

Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.

Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, Atoyan R, Qu H, Yin L, Samson M, Zifcak B, Ma AW, DellaRocca S, Borek M, Zhai HX, Cai X, Voi M.

Clin Cancer Res. 2012 Aug 1;18(15):4104-13. doi: 10.1158/1078-0432.CCR-12-0055. Epub 2012 Jun 12.

9.

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.

Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C.

Neuro Oncol. 2010 Dec;12(12):1205-19. doi: 10.1093/neuonc/noq103. Epub 2010 Sep 22.

10.

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA.

Oncotarget. 2012 Apr;3(4):371-94. Review.

11.

Fluorescent lipids as probes for sphingosine kinase activity by capillary electrophoresis.

Yangyuoru PM, Hammonds-Odie L, Mwongela SM.

Methods Mol Biol. 2013;984:329-40. doi: 10.1007/978-1-62703-296-4_24.

PMID:
23386355
12.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Review.

PMID:
24333502
13.

Methods to measure the enzymatic activity of PI3Ks.

Ciraolo E, Gulluni F, Hirsch E.

Methods Enzymol. 2014;543:115-40. doi: 10.1016/B978-0-12-801329-8.00006-4.

PMID:
24924130
14.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

15.

Low mobility of phosphatidylinositol 4,5-bisphosphate underlies receptor specificity of Gq-mediated ion channel regulation in atrial myocytes.

Cho H, Kim YA, Yoon JY, Lee D, Kim JH, Lee SH, Ho WK.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15241-6. Epub 2005 Oct 10.

16.

PI 3-kinase independent role for AKT in F-actin regulation during outer segment phagocytosis by RPE cells.

Bulloj A, Duan W, Finnemann SC.

Exp Eye Res. 2013 Aug;113:9-18. doi: 10.1016/j.exer.2013.05.002. Epub 2013 May 10.

17.

Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.

Andrs M, Korabecny J, Jun D, Hodny Z, Bartek J, Kuca K.

J Med Chem. 2015 Jan 8;58(1):41-71. doi: 10.1021/jm501026z. Epub 2014 Dec 5.

PMID:
25387153
18.

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15. Review.

19.

Phosphatidylinositol 3-kinase affects mitochondrial function in part through inducing peroxisome proliferator-activated receptor γ coactivator-1β expression.

Gao M, Wang J, Wang W, Liu J, Wong CW.

Br J Pharmacol. 2011 Feb;162(4):1000-8. doi: 10.1111/j.1476-5381.2010.01105.x.

20.

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.

PMID:
23832540

Supplemental Content

Support Center